We’re excited to share that GlioCART, our CAR-T cell therapy project for glioblastoma, was selected for Venture Kick Stage 2, securing CHF 40’000 in support (June 2025). This milestone helps accelerate our translational work towards targeted, durable immunotherapies for GBM.
Read more at Venture Kick: GlioCART project page.